NCT04939051 2026-03-18
Obeticholic Acid for Prevention in Barrett's Esophagus
National Cancer Institute (NCI)
Phase 2 Recruiting
Clinical Trials
125 trialsNCT06732388 2026-03-18
Itraconazole in Combination With Ablation for the Prevention of Esophageal Cancer in Patients With High-risk Barrett's Esophagus
National Cancer Institute (NCI)
Phase 2 Not yet recruiting
NCT07282912 2026-03-04
OLIGOMETS
Yale University
Phase 2 Recruiting
NCT05329766 2026-02-27
EDGE-Gastric
Arcus Biosciences, Inc.
Phase 2 Active not recruiting
NCT07432295 2026-02-25
Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)
I-Mab Biopharma US Limited
Phase 2 Recruiting
NCT04430738 2026-02-24
Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers
Seagen Inc.
Phase 2 Active not recruiting
NCT05945823 2025-12-29
Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors
Taiho Oncology, Inc.
Phase 2 Active not recruiting
NCT06161818 2025-12-22
TNT-OES-2
Erasmus Medical Center
Phase 2 Recruiting
NCT06251973 2025-12-02
A Study of agenT-797 in Combination With Botensilimab, Balstilimab, Ramucirumab, and Paclitaxel for People With Esophageal, Gastric, or Gastro-esophageal Junction Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT06846346 2025-11-28
GRACIE
UNICANCER
Phase 2 Recruiting
NCT01142388 2025-11-25
Paclitaxel With or Without Cixutumumab as Second-Line Therapy in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT07223424 2025-11-10
PSI-Immune
University of Pittsburgh
Phase 2 Recruiting
NCT02521285 2025-10-23
Aspirin in Preventing Disease Recurrence in Patients With Barrett Esophagus After Successful Elimination by Radiofrequency Ablation
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT03161522 2025-10-23
Chemotherapy With or Without Radiation or Surgery in Treating Participants With Oligometastatic Esophageal or Gastric Cancer
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT05104567 2025-09-24
A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Gastrointestinal Cancer (Master Protocol) (Pegathor Gastrointestinal 203)
Sanofi
Phase 2 Completed
NCT04929392 2025-09-04
Chemoradiation and Pembrolizumab Followed by Pembrolizumab and Lenvatinib Before Surgery for the Treatment of Non-metastatic Esophageal or Esophageal/Gastroesophageal Junction Cancer
City of Hope Medical Center
Phase 2 Active not recruiting
NCT06687876 2025-07-10
MEMENTO
Amsterdam UMC, location VUmc
Phase 2 Recruiting
NCT06933966 2025-04-18
ATTENUATION
Centre Leon Berard
Phase 2 Not yet recruiting
NCT04114136 2025-02-10
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
University of Pittsburgh
Phase 2 Recruiting
NCT05476796 2024-10-24
LOGICAN
UNICANCER
Phase 2 Recruiting
NCT05713838 2024-09-19
Organ Preservation With Durvalumab-based Immunotherapy in Combination With Chemoradiation as Definitive Therapy for Early Stage Esophageal Adenocarcinoma With Indication for Radical Surgery
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2 Recruiting
NCT05177133 2024-08-02
AuspiCiOus
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Phase 2 Recruiting
NCT04159974 2024-05-09
RICE
University of Cologne
Phase 2 Unknown
NCT03339843 2024-03-15
MiMe-A
Jules Bordet Institute
Phase 2 Completed
NCT02830594 2024-02-20
Pembrolizumab and Palliative Radiation Therapy in Treating Patients With Metastatic Esophagus, Stomach, or Gastroesophageal Junction Cancer
City of Hope Medical Center
Phase 2 Completed
NCT02037048 2024-01-08
FOLFOX-6 Induction Chemotherapy Followed by Esophagectomy and Post-operative Chemoradiotherapy in Patients With Esophageal Adenocarcinoma
Case Comprehensive Cancer Center
Phase 2 Unknown
NCT03783936 2023-12-19
Trial of mFOLFOX6 + Trastuzumab + Avelumab in Gastric and Esophageal Adenocarcinomas
Hoosier Cancer Research Network
Phase 2 Completed
NCT01307956 2023-10-26
Panitumumab, Combination Chemotherapy, & Radiation Therapy in Esophageal or Gastroesophageal Junction Cancer
University of Nebraska
Phase 2 Terminated
NCT02971956 2023-09-21
Pembrolizumab in Refractory Advanced Esophageal Cancer
Dana-Farber Cancer Institute
Phase 2 Completed
NCT00551759 2023-07-03
Chemotherapy, Radiation Therapy, and Cetuximab Followed by Surgery, Docetaxel, and Cetuximab in Treating Patients With Esophageal Cancer or Gastroesophageal Junction Cancer
Eastern Cooperative Oncology Group
Phase 2 Terminated
NCT00033657 2023-06-28
Radiation Therapy and Chemotherapy Before and After Surgery in Treating Patients With Esophageal Cancer
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT00003237 2023-06-22
Combination Chemotherapy After Surgery in Treating Patients With Cancer of the Esophagus or Stomach
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT01333033 2023-04-13
PET Scan Imaging in Assessing Response in Patients With Esophageal Cancer Receiving Combination Chemotherapy
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT05745857 2023-02-27
SLURP
University Medical Center Groningen
Phase 2 Unknown
NCT03399071 2023-02-21
ICONIC
Royal Marsden NHS Foundation Trust
Phase 2 Unknown
NCT03982173 2023-01-26
MATILDA
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2 Withdrawn
NCT01212822 2022-09-07
Bevacizumab and Combination Chemotherapy Before Surgery in Treating Patients With Locally Advanced Esophageal or Stomach Cancer
Fox Chase Cancer Center
Phase 2 Completed
NCT00573131 2022-06-22
Efficacy and Safety of OncoGelâ„¢ Added to Chemotherapy and Radiation Before Surgery in Subjects With Esophageal Cancer
Boston Scientific Corporation
Phase 2 Terminated
NCT03365791 2022-05-27
PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies
Novartis
Phase 2 Completed
NCT03592407 2022-03-08
Epacadostat and Pembrolizumab Before Surgery in Treating Participants With Stage II-III Esophageal or Gastroesophageal Cancer
City of Hope Medical Center
Phase 2 Withdrawn
NCT01298999 2021-11-23
Trial of a Gastrin Receptor Antagonist in Barrett's Esophagus
Columbia University
Phase 2 Completed
NCT04018872 2021-11-04
Evaluating the Effect of Itraconazole on Pathologic Complete Response Rates in Esophageal Cancer
Dallas VA Medical Center
Phase 2 Recruiting
NCT00591123 2021-10-01
Study of Erlotinib and Chemotherapy for Unresectable or Metastatic Cancer of the Esophagus and Gastric Cardia
Translational Oncology Research International
Phase 2 Completed
NCT00381706 2021-09-29
Combination Chemotherapy and Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT00003487 2021-05-14
Antineoplaston Therapy in Treating Patients With Cancer of the Esophagus
Burzynski Research Institute
Phase 2 Terminated
NCT02128243 2021-03-26
MATEO
AIO-Studien-gGmbH
Phase 2 Completed
NCT00006472 2020-08-18
Combination Chemotherapy Plus Radiation Therapy Followed By Surgery in Treating Patients With Stage I, Stage II, or Stage III Esophageal Cancer
Medstar Health Research Institute
Phase 2 Terminated
NCT00003748 2020-08-03
Irinotecan in Treating Patients With Esophageal or Stomach Cancer
Jonsson Comprehensive Cancer Center
Phase 2 Completed
NCT00020761 2020-08-03
Irinotecan and Paclitaxel in Treating Patients With Metastatic or Recurrent Cancer of the Esophagus or Stomach
Jonsson Comprehensive Cancer Center
Phase 2 Completed
NCT02241499 2020-02-28
PALAESTRA
Lund University Hospital
Phase 2 Completed